Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CFO Sells 12,500 Shares of Stock

Key Points

• CFO sale: Spyre CFO Scott Burrows sold 12,500 shares on May 1 at an average price of $71.37 for total proceeds of $892,125 under a pre‑arranged Rule 10b5‑1 plan, reducing his stake by 11.31% to 97,994 shares (≈$6.99M) per an SEC filing.
• Market and analyst context: Shares traded at $69.42 on Friday (1‑year range $12.28–$76) with a market cap of ~$5.47B and negative EPS, while multiple analysts lifted targets (up to $106) and the stock holds a consensus "Buy" rating with a $85.08 price target.

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CFO Scott Burrows sold 12,500 shares of the firm's stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $71.37, for a total value of $892,125.00. Following the sale, the chief financial officer owned 97,994 shares of the company's stock, valued at $6,993,831.78. This represents a 11.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Spyre Therapeutics Price Performance

SYRE traded down $5.03 on Friday, reaching $69.42. The company's stock had a trading volume of 1,463,178 shares, compared to its average volume of 1,426,069. Spyre Therapeutics, Inc. has a 1 year low of $12.28 and a 1 year high of $76.00. The business's 50 day moving average is $51.75 and its 200 day moving average is $37.36. The stock has a market cap of $5.47 billion, a price-to-earnings ratio of -33.38 and a beta of 3.12.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last announced its earnings results on Thursday, February 19th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.04). As a group, research analysts forecast that Spyre Therapeutics, Inc. will post -2.8 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Robert W. Baird lifted their price target on Spyre Therapeutics from $65.00 to $90.00 and gave the stock an "outperform" rating in a research note on Tuesday, April 14th. Wedbush raised their price target on shares of Spyre Therapeutics from $65.00 to $80.00 and gave the stock an "outperform" rating in a research report on Monday, April 13th. Leerink Partners boosted their price objective on shares of Spyre Therapeutics from $49.00 to $106.00 and gave the company an "outperform" rating in a research report on Monday, April 13th. Jefferies Financial Group raised their target price on shares of Spyre Therapeutics from $47.00 to $85.00 and gave the stock a "buy" rating in a report on Monday, April 13th. Finally, Wall Street Zen lowered Spyre Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, April 26th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $85.08.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. RTW Investments LP lifted its holdings in Spyre Therapeutics by 15.2% in the fourth quarter. RTW Investments LP now owns 4,171,996 shares of the company's stock worth $136,675,000 after purchasing an additional 550,000 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Spyre Therapeutics by 32.3% in the fourth quarter. Vanguard Group Inc. now owns 4,035,074 shares of the company's stock valued at $132,189,000 after acquiring an additional 984,344 shares in the last quarter. Capital International Investors increased its stake in shares of Spyre Therapeutics by 46.0% during the fourth quarter. Capital International Investors now owns 3,492,541 shares of the company's stock valued at $114,416,000 after acquiring an additional 1,100,000 shares during the period. Perceptive Advisors LLC raised its holdings in Spyre Therapeutics by 149.6% during the fourth quarter. Perceptive Advisors LLC now owns 3,069,225 shares of the company's stock worth $100,548,000 after purchasing an additional 1,839,780 shares in the last quarter. Finally, Commodore Capital LP lifted its position in Spyre Therapeutics by 20.1% in the fourth quarter. Commodore Capital LP now owns 2,388,245 shares of the company's stock worth $78,239,000 after purchasing an additional 400,161 shares during the period. 80.39% of the stock is owned by institutional investors and hedge funds.

About Spyre Therapeutics

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.